





Have Questions?



Type them into questions box!

“Why am I muted?”

Don't worry. Everyone is muted except the presenter and host. Thank you and enjoy the show.

Contact ACS Webinars® at acswebinars@acs.org



@AmericanChemicalSociety



@AmerChemSociety



@AmerChemSociety



<https://www.linkedin.com/company/american-chemical-society>

Contact ACS Webinars® at acswebinars@acs.org

Check out the Archive!

An ACS member exclusive benefit



Hundreds of presentations from the best and brightest minds that chemistry has to offer are available to you on-demand. The Archive is divided into 6 different sections to help you more easily find what you are searching.

Professional Development

▶ View the Collection

Learn how to write better abstracts, deliver more engaging presentations, and network to your next dream job. Brush up on your soft skills and set a new career path by mastering what can not be taught in the lab.

Technology & Innovation

▶ View the Collection

From renewable fuels to creating the materials for the technology of tomorrow, chemistry plays a pivotal role in advancing our world. Meet the chemists that are building a better world and see how their science is making it happen.

Drug Design and Delivery

▶ View the Collection

The Drug Design Delivery Series has built a collection of the top minds in the field to explain the mechanics of drug discovery. Discover the latest research, receive an overview on different fields of study, and gain insight on how to possibly overcome your own med chem roadblocks.

Culinary Chemistry

▶ View the Collection

Why does food taste better when it is grilled or what molecular compounds make a great wine? Discover the delectable science of your favorite food and drink and don't forget to come back for a second helping.

Popular Chemistry

▶ View the Collection

Feeling burdened by all that molecular weight? Listen to experts expound on the amazing side of current hot science topics. Discover the chemistry of rockets, how viruses have affected human history, or the molecular breakdown of a hangover.

Business & Entrepreneurship

▶ View the Collection

How do ideas make it from the lab to the real world? Discover the ins and outs of the chemical industry whether you are looking to start a business or desire a priceless industry-wide perspective.

<https://www.acs.org/content/acs/en/acs-webinars/videos.html>

3



ACS Webinars®

CLICK • WATCH • LEARN • DISCUSS



Learn from the best and brightest minds in chemistry! Hundreds of webinars on diverse topics presented by experts in the chemical sciences and enterprise.

Edited Recordings are an exclusive ACS member benefit and are made available to registrants via an email invitation once the recording has been edited and posted.

Live Broadcasts of ACS Webinars® continue to be available to the general public on Tuesdays, Wednesdays, and Thursdays from 2-3pm ET!

A collection of the best recordings from the ACS Webinars Archive will be broadcast on Mondays and Fridays from 2-3pm ET!

www.acs.org/acswebinars

4

What is ACS on Campus?



ACS visits campuses across the world offering FREE seminars on how to be published, find a job, network and use essential tools like SciFinder. ACS on Campus presents seminars and workshops focused on how to:




- Publish in top journals
- Find a job
- Effectively use research tools like SciFinder® and ACS ChemWorx
- Communicate your science
- Write grant proposals
- Build industry partnerships
- Prepare for a changing employment landscape

<http://acsoncampus.acs.org>

5

An individual development planning tool for you!



<https://chemidp.acs.org>

6

From ACS Industry Member Programs

◆ Industry Matters Newsletter

Exclusive interviews with industry leaders and insights to advance your career

Preview & Subscribe: acs.org/indnews



Connect, collaborate, and stay informed about the trends leading chemical innovation

Join: bit.ly/ACSinnovationhub



Contact Us:

2107 Wilson Blvd
#700
Arlington, VA 22201

(703)243-2800
aaps@aaps.org

AAPS Membership
membership@aaps.org
(877)998-2277 (AAPS)



WHO WE ARE

Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 7,000 individual members and over 10,000 actively participating stakeholders employed in academia, industry, government, and other pharmaceutical science related research institutes worldwide.

Our mission:

To advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health

Our vision:

Advancing the pharmaceutical sciences to drive prevention and cures.

Our five core values:


Learning, Innovation, Service, Inclusiveness and Integrity.

AAPS is incorporated as a not-for-profit organization under the U. S. Internal Revenue Service Code, 501(c)3 in the District of Columbia.

Members of the American Association of Pharmaceutical Scientists (AAPS) gathered during the 2013 AAPS Annual Meeting and Exposition to discuss why they chose a career in pharmaceutical sciences and how AAPS has helped foster their journey. The I Am AAPS video series displays the diversity of AAPS membership while exhibiting one common goal: to impact global health.

<https://www.aaps.org>

Join the Division Today!



For \$25 membership (\$10 for students), You Will Receive:

- A free digital copy of our annual medicinal chemistry review volume (over 680 pages, \$160 retail price)
- Abstracts of MEDI programming at national meetings
- Access to student travel grants and fellowships



Find out more about the ACS MEDI Division! www.acsmedchem.org

9

Free ACS Webinars Everyday!

Tomorrow




FREE Rebroadcast | Fri, May 1 at 2pm ET
 







































<https://www.acs.org/content/acs/en/acs-webinars/culinary-chemistry/flavor-rebroadcast.html>

10

Over 60 Drug Discovery Webinars!


<http://bit.ly/acsDrugDiscoveryArchive>



 Drug Discovery Series #1 - Current Drug Discovery and Development Processes JCCD will explore the state of the drug discovery and development process to learn the progress and challenges in each field.	 Designing Better Drug Candidates Current design methods follow the lead to improve molecular quality from C ₁ to Lead.	 Drug Target Kinetics in Drug Design Ligand Binding Kinetics (LBK) is used to improve the molecular quality of drug candidates.	 Fighting Cancer - Targeting CDK Inhibitors with Kinase Inhibitors Tosny Hefner will discuss the latest data for CDK inhibitors and their potential for cancer treatment.	 A New Strategy in Drug Discovery: Protein-Directed Protein Synthesis Chen-Ching Chang will discuss the latest data for protein-directed protein synthesis and its potential for drug discovery.	 What's New in Drug Discovery - Insights from Molecular Modeling Scott F. May will discuss the latest data for molecular modeling and its potential for drug discovery.
 From an Old Target Class JCCD will explore a discussion on the drug target class and the challenges associated with this target class.	 Emerging to Improve Solubility of Drug Candidates Cecilia Laine will discuss the latest data for emerging technologies to improve drug solubility.	 Long-Acting Injectable Medications: Design and Development Considerations Mehmet Ozkan will discuss the latest data for long-acting injectable medications and their development considerations.	 Fighting Cancer - Emerging Targets for Oncology Phyllis Start Gomez will discuss the latest data for emerging targets in oncology and their potential for cancer treatment.	 Women in Drug Discovery and Development: How to Succeed in a Male-Dominated Field Lizbeth G. Lopez will discuss the latest data for women in drug discovery and development and how to succeed in a male-dominated field.	 Current Research in Drug Discovery - Insights from Molecular Modeling Scott F. May will discuss the latest data for current research in drug discovery and insights from molecular modeling.
 Key Considerations in Identifying Drug Leads JCCD will discuss how drug discovery is becoming more data-driven and how this is affecting the way we identify drug leads.	 Fragment Based Drug Design Strategies Michael J. Griffin will discuss the latest data for fragment based drug design strategies and their potential for drug discovery.	 Molecular Modeling Formulation for Solubility, Storage and Stability Mehmet Ozkan will discuss the latest data for molecular modeling formulation for solubility, storage and stability.	 Fighting Cancer - Kinase and Targeting Cancer Cell Metabolism Mehmet Ozkan will discuss the latest data for fighting cancer - kinase and targeting cancer cell metabolism.	 Biotechnology Overview for mRNA Delivery: Introduction Mehmet Ozkan will discuss the latest data for biotechnology overview for mRNA delivery: introduction.	 Women in the Biotech Industry: Challenges and Opportunities Lizbeth G. Lopez will discuss the latest data for women in the biotech industry: challenges and opportunities.
 Using Optimal - Binding Efficiency & Safety JCCD will discuss how drug discovery is becoming more data-driven and how this is affecting the way we identify drug leads.	 Screening Strategies Mehmet Ozkan will discuss the latest data for screening strategies and their potential for drug discovery.	 The Medical Center of Tennessee Mehmet Ozkan will discuss the latest data for the Medical Center of Tennessee and its potential for drug discovery.	 Cyclic Peptides: Discovery of CTRP Modulators Mehmet Ozkan will discuss the latest data for cyclic peptides: discovery of CTRP modulators.	 Biotechnology Overview for mRNA Delivery: Introduction Mehmet Ozkan will discuss the latest data for biotechnology overview for mRNA delivery: introduction.	 Women in the Biotech Industry: Challenges and Opportunities Lizbeth G. Lopez will discuss the latest data for women in the biotech industry: challenges and opportunities.
 How to Find the Right and Starting your Clinical Trial JCCD will discuss how drug discovery is becoming more data-driven and how this is affecting the way we identify drug leads.	 Avoiding PAINS (pan-assay interference compound) Mehmet Ozkan will discuss the latest data for avoiding PAINS (pan-assay interference compound) and their potential for drug discovery.	 Design of Deliverable Biosensors Mehmet Ozkan will discuss the latest data for design of deliverable biosensors and their potential for drug discovery.	 Antibodies: Rational Approaches to the Design and Optimization Mehmet Ozkan will discuss the latest data for antibodies: rational approaches to the design and optimization.	 Biotechnology Overview for mRNA Delivery: Introduction Mehmet Ozkan will discuss the latest data for biotechnology overview for mRNA delivery: introduction.	 Women in the Biotech Industry: Challenges and Opportunities Lizbeth G. Lopez will discuss the latest data for women in the biotech industry: challenges and opportunities.
 The Role of Chemistry in Clinical Trials: The Big Expense & Biggest Challenge JCCD will discuss how drug discovery is becoming more data-driven and how this is affecting the way we identify drug leads.	 Accelerating CDK Inhibitor Discovery: Fragment Based Design Mehmet Ozkan will discuss the latest data for accelerating CDK inhibitor discovery: fragment based design.	 Enabling Big and Thinking Small: Adapting Molecular Chemistry Strategy for Molecular Drug Candidates Mehmet Ozkan will discuss the latest data for enabling big and thinking small: adapting molecular chemistry strategy for molecular drug candidates.	 Antibodies: Rational Approaches to the Design and Optimization Mehmet Ozkan will discuss the latest data for antibodies: rational approaches to the design and optimization.	 Biotechnology Overview for mRNA Delivery: Introduction Mehmet Ozkan will discuss the latest data for biotechnology overview for mRNA delivery: introduction.	 Women in the Biotech Industry: Challenges and Opportunities Lizbeth G. Lopez will discuss the latest data for women in the biotech industry: challenges and opportunities.
 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Key Considerations in Identifying Drug Leads JCCD will discuss how drug discovery is becoming more data-driven and how this is affecting the way we identify drug leads.	 Novel Anti-Thrombotic: Making Sense of Antifibrinolytic Mehmet Ozkan will discuss the latest data for novel anti-thrombotic: making sense of antifibrinolytic.	 Wax Hepatitis: The Search for a Cure Mehmet Ozkan will discuss the latest data for wax hepatitis: the search for a cure.	 How to Optimize Central Nervous System Therapeutics Mehmet Ozkan will discuss the latest data for how to optimize central nervous system therapeutics.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.
 Delivery Options to Support Drug Evaluation in Preclinical Toxicology and Pharmacokinetics: Safety, Stability, and Efficacy Mehmet Ozkan will discuss the latest data for delivery options to support drug evaluation in preclinical toxicology and pharmacokinetics: safety, stability, and efficacy.	 Challenges and Trends in Solid Dosage Form Selection Mehmet Ozkan will discuss the latest data for challenges and trends in solid dosage form selection.	 Crystallization as a Drug Design and Delivery Tool Mehmet Ozkan will discuss the latest data for crystallization as a drug design and delivery tool.	 Novel Molecularly Targeted: Novel Approaches for Treatment Mehmet Ozkan will discuss the latest data for novel molecularly targeted: novel approaches for treatment.	 A Novel Strategy for the Treatment of Chronic Pain: Antagonizing P2X7 with a Macrocyclic Peptide Mehmet Ozkan will discuss the latest data for a novel strategy for the treatment of chronic pain: antagonizing P2X7 with a macrocyclic peptide.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.
 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.
 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.	 Pharmaceuticals and the Challenges of Drug Discovery Mehmet Ozkan will discuss the latest data for pharmaceuticals and the challenges of drug discovery.

CO-PRODUCED BY



HOW DO DRUGS REALLY GET INTO CELLS?

WHY PASSIVE BILAYER DIFFUSION IS A MYTH

THIS ACS WEBINAR WILL BEGIN SHORTLY...



How Drugs Really Get Into Cells: Why Passive Bilayer Diffusion is a Myth



Douglas Kell
Professor of Systems Biology, Department
of Biochemistry, University of Liverpool



Michael Sinz
Senior Research Fellow,
Bristol-Myers Squibb

Presentation slides are available now! Edited recordings are an exclusive ACS member benefit.

www.acs.org/acswebinars

This ACS Webinar is co-produced with ACS Division of Medicinal Chemistry, American Association of Pharmaceutical Scientists, and ACS Publications.

13

ACS Chemistry for Life® aaps ACS Technical Division Medicinal Chemistry (MED) ACS Publications Most Trusted. Most Cited. Most Read.

HOW DO DRUGS REALLY GET INTO CELLS?

WHY PASSIVE BILAYER DIFFUSION IS A MYTH

Douglas Kell
University of Liverpool

Dept of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool L69 9BZ, U.K.
Novo Nordisk Fonden Centre for Biosustainability
Danish Technical University, 2800 Lyngby, Denmark

<http://dbkgroup.org/publications/>

@dbkell

dbk@liv.ac.uk

14

Take-Home Messages




- There is not much phospholipid bilayer in real cell membranes, and most diffusion through it is **negligible**
- Uptake is mainly determined by **biology**, not physical chemistry
- Transporters (SoLute Carriers, SLCs) easily explain heterogeneity of cell/tissue uptake, including via blood brain barrier
- Systems biology approaches are required


Background – Drug Discovery




Forward and reverse (chemical) genomics in drug discovery



High Attrition



Attrition: ~90% of new molecules fail to make it to the clinic, even from phase I



Smietana, et al. (2016). Nat Rev Drug Disc 15: 379-380

Issues of Attrition




- **Gross** PK/PD seen as less of an issue in last decade
- Now mostly due to (i) **lack of efficacy**, (ii) **toxicity**
- Both problems are underpinned by the fact that drugs are typically first developed on the basis of isolated molecular assays before being tested in the intact system
- These failures turn drug discovery – if it was not already – into a problem of systems biology

Herrgård et al., Nat Biotechnol 26, 1155-60 (2008)



A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology

Markus J Herrgård^{1,19,20}, Neil Swainston^{1,3,20}, Paul Dobson^{1,4}, Warwick B Dunn^{1,4}, K Yukin Ang¹, Mikko Arvola¹, Niels Blüthgen^{1,7}, Simon Borge¹, Roeland Costenoble¹, Matthias Heinemann¹, Michael Huska¹⁰, Nicolas Le Novère¹¹, Peter Li¹², Wolfram Liebermeister⁸, Monica L Mo⁷, Ana Paula Oliveira¹², Dina Petramovic^{12,13,14}, Stephen Pentler¹⁵, Evangelos Simeonidis¹⁷, Kieran Smallbone^{1,12}, Irena Spasic¹⁵, Dieter Weichart^{1,18}, Roger Beant^{1,6}, David S Broomhead¹¹, Hans V Westerhoff^{17,18}, Bernd Kuster¹⁶, Maria Penttilä¹⁶, Edda Klipp¹⁶, Bernhard O Palsson¹, Uwe Sauer⁸, Stephen G Oliver^{1,6}, Pedro Mendes^{1,3,11}, Jens Nielsen^{12,11} & Douglas B Kell^{1,4,1}



Human network, Nature Biotechnol 31, 419-425 (2013)



A community-driven global reconstruction of human metabolism

Ines Thiele^{1,2,3,6}, Neil Swainston^{3,4,3,6}, Ronan M T Fleming^{1,5}, Andreas Hoppe⁶, Swagatika Sahoo¹, Maike K Aurich¹, Hulda Haraldsdottir¹, Monica L Mo⁷, Ottar Rolfsson¹, Miranda D Stobbe^{8,9}, Stefan G Thorleifsson¹, Rasmus Agren¹⁰, Christian Bölling⁸, Sergio Bordel¹⁰, Arvind K Chavali¹¹, Paul Dobson¹², Warwick B Dunn^{2,13}, Lukas Endler¹⁴, David Hala¹⁵, Michael Huska^{1,6}, Duncan Hull¹, Daniel Jameson^{3,4}, Neema Jamshidi⁷, Jon J Jonsson⁵, Nick Juty¹⁷, Sarah Keating¹⁷, Intawat Nookaew¹⁰, Nicolas Le Novère^{17,18}, Naglis Malys^{3,19,20}, Alexander Mazein²¹, Jason A Papin¹¹, Nathan D Price²², Evgeni Selkov, Sr²³, Martin I Sigurdsson¹, Evangelos Simeonidis^{22,24}, Nikolaus Sonnenschein²⁵, Kieran Smallbone^{3,26}, Anatoly Sorokin^{21,27}, Johannes H G M van Beek²⁸⁻³⁰, Dieter Weichart^{3,31}, Igor Goryanin^{21,32}, Jens Nielsen¹⁰, Hans V Westerhoff^{3,28,33}, Douglas B Kell^{3,34}, Pedro Mendes^{3,4,35} & Bernhard O Palsson^{1,7}

7440 reactions (~1/3 transport), 5,063 metabolites, 2,626 unique metabolites

Freely available at <http://humanmetabolism.org/>

Predicts e.g. Inborn errors of metabolism, exometabolites, drug actions, cellular differences



Crossing Membranes



23

Nat Rev Drug Disc 7, 205-220 (2008)



PERSPECTIVES

OPINION

Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?


Paul D. Dobson and Douglas B. Kell

The types of biophysical forces that determine the interaction of drugs with lipids (especially hydrophobic and hydrogen-bonding interactions) are no different from those involved in their interaction with proteins, especially hydrophobic transport proteins. Therefore, biophysical arguments alone cannot make a mechanistic distinction between the two modes of transport that are outlined in FIG. 1. Indeed, four lines of reasoning together suggest that carrier-mediated




24

How drugs can cross cellular membranes



By free diffusion or carrier-mediated?

Regular misuse of the word 'passive'



1. A thermodynamic usage, to mean equilibrative rather than concentrative

Purely thermodynamic; no mechanism is implied, nor could be

2. A mechanistic usage, typically implying 'through or across the bilayer'

Usually does not admit to this intended meaning, or simply assumes it. Often conflated with 1.

The terminology of transport reactions




Avoid the use of “passive” – it has too much baggage


Means of Transport

		Purely lipoidal	Transporter-mediated
Thermodynamics	Concentrative	Concentrative bilayer diffusion (may be driven by e.g. a pH gradient or membrane potential)	Active transport
	Equilibrative	Simple or equilibrative bilayer diffusion	Facilitated diffusion

Singer & Nicolson, Science 1972



Protein:lipid ~1:10



In real biological membranes there is little or no **unperturbed** bilayer: Dupuy AD, Engelman DM: Protein area occupancy at the center of the red blood cell membrane. PNAS (2008) 105, 2848-2852.




Drug Disc Today 16, 704-714 (2011)



Pharmaceutical drug transport: The issues and the implications that it is essentially carrier-mediated only


Nu Douglas B. Kell^{1,2}, Paul D. Dobson^{1,2,3} and Stephen G. Oliver^{4,5}



Symbol size proportional to carriers per Mbase




SoLuteCarriers (SLCs) & ATP-Binding Cassette (ABC) transporters




- ~500 SLCs (mainly influxers/ antiporters)
- ~50 ABCs (mainly effluxers)
- Up to 4% of genes involved in transport
- Bioparadigms.org

A typical biomembrane drawn to scale



Antje Kell

Membrane with aquaporin



No water is crossing
via phospholipids

http://www3.mpibpc.mpg.de/groups/de_groot/gallery/aqp1_snapshot.jpg

Two Views



molecular
pharmaceutics

11, 1727-1738 (2014)

Review

pubs.acs.org/molecularpharmaceutics

Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake Are Both Important Mechanisms of Membrane Permeation in Drug Disposition

Dennis Smith,^{*,†} Per Artursson,[‡] Alex Avdeef,[§] Li Di,^{||} Gerhard F. Ecker,[⊥] Bernard Faller,[#]
J. Brian Houston,[¶] Manfred Kansy,[□] Edward H. Kerns,[■] Stefanie D. Krämer,[○] Hans Lennernäs,[‡]
Han van de Waterbeemd,[●] Kiyohiko Sugano,[△] and Bernard Testa[▲]

frontiers in
PHARMACOLOGY

5, 231 (2014) (32pp)

REVIEW ARTICLE
published: 31 October 2014
doi: 10.3389/fphar.2014.00231



How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion

**Phospholipid Bilayer
diffusion Is Negligible (PBIN)**

Douglas B. Kell^{1,2*} and Stephen G. Oliver^{3,4}

Placating the corn God



Hypothesis: The corn God must be placated to get good yields of corn;

Add **fish** when planting corn

→ Good yield

this is done by sacrificing a fish




Inference: the data show that the corn God (although she is never measured directly) is important for (i.e. involved mechanistically in determining) the measured output (maize yield)

No fish at planting time gives poor yields

Placating the bilayer lipoidal diffusion God

Hypothesis: Lipoidal bilayer diffusion is important in cellular drug uptake

Add drug external to cells and make a **wish** that it enters → Drug measured inside cells



Inference: the data show that the lipoidal bilayer diffusion God (although it is never measured directly) is important for (i.e. involved mechanistically in determining) the measured output (drugs in cells)

(No) drug added external to cells

→ (No) drug measured inside cells

Measuring outcomes is not the same as measuring mechanisms

Position statement (\equiv hypothesis)



- There is in fact **no actual evidence** (**evidence = data plus correct theory and interpretation**) that any significant drug permeability goes via undisturbed lipid bilayers in real (undamaged) biomembranes
- In the presence of potentially 100s of carriers that might serve to transport drugs it is very hard to obtain it
- Think if your own data are consistent with this

Counterfactuals that lipid-only theories need (and fail) to explain



1. Why most drugs do not diffuse across the blood-brain barrier (and others) where the lipids are not significantly different
2. The substantially varying tissue and species distributions in cellular drug uptake



37

Audience Survey Question

ANSWER THE QUESTION ON BLUE SCREEN IN ONE MOMENT



38

Do you think CO₂ crosses intact cellular membranes by using a transporter?

- No. 100% via bilayer, for sure
- Probably through the bilayer
- Probably needs a protein transporter
- Yes, 100% - definitely needs a transporter
- Other (Tell us more in the chat)

** If your answer differs greatly from the choices above tell us in the chat!*

It needs a transporter, of course



BBA 1840, 1592-5 (2014) Biochimica et Biophysica Acta 1840 (2014) 1592–1595



Contents lists available at ScienceDirect

Biochimica et Biophysica Acta

journal homepage: www.elsevier.com/locate/bbagen



Review

Aquaporins and membrane diffusion of CO₂ in living organisms[☆]

Ralf Kaldenhoff*, Lei Kai, Norbert Uehlein

Department of Biology, Applied Plant Sciences, Technische Universität Darmstadt, Schmittspahnstrasse 10, D-64287 Darmstadt, Germany



39

Drug Transport – Lipinski's 'Rule of 5'




- **Poor absorption or permeation is more likely when**
- **H-bond donors > 5**
- **H-bond acceptors > 10**
- **MW > 500, and**
- **calculated Log P (CLogP) > 5**

Lipinski *et al.*, *Adv Drug Delivery Rev* 46, 3-26 (2001) (reprint of 1997 version)



40

Lipinski Ro5




- While empirical, it effectively imputes a trade-off between lipophilicity to cross membranes and hydrophilicity to ensure aqueous solubility

- Lipinski's Rule-of-5 for determining the likely bioavailability of a compound does **implicitly** assume the pre-eminence of the lipid diffusion route as it **explicitly** classes carrier-mediated transport as an exception

- Navitoclax.2HCl – $C_{47}H_{57}Cl_3F_3N_5O_6S_3$, MW**1047.53**, 7 ring systems!


“Overton's Rule” (1899)



- Permeability coefficients of nonelectrolytes across biomembranes correlate well with olive oil/water partition coefficients.
- (nowadays octanol is more typically used)
- $\text{Log } K_{o/w} \equiv \text{log } D \text{ or sometimes log } P$

Lieb & Stein, Nature 224, 220-3 (1969)

Poor relationship between Caco-2 permeability and $\log K_{o/w}$ ($\log P$)



THESE $\log P$
THEORIES OF DRUG
UPTAKE
ARE BIOPHYSICAL,
'LIPID-ONLY'
THEORIES

Corti *et al.* Eur J Pharm Sci 7, 354-362 (2006)



43

Narcotics ('general anaesthetics')



- Potency also correlates with $\log P$ (up to a cut-off) (Meyer & Overton)
- Was assumed that they also act by a 'biophysical' mechanism by partitioning 'nonspecifically' into membrane and e.g. 'squeezing' nerve channels



44

Anaesthetic potency does largely correlate with partitioning into membrane



MEMBRANE ACTIONS OF ANESTHETICS AND TRANQUILIZERS 601





FIG. 9. Showing that the nerve-blocking (or antihemolytic) concentration of an anesthetic directly correlates with the membrane/buffer partition coefficient. See table 5 for code to anesthetics.

P. Seeman, Pharmacol Rev 24, 583-655 (1972) (>2800 citations!)




Relationship between ability to inhibit the soluble enzyme luciferase and narcotic potency in animals



Franks & Lieb, Nature 310, 599-601 (1984)



The structural basis is known



Binding of bromoform to luciferase

Franks *et al.*, *Biophys J* 75, 2205-11 (1998)

The biophysical forces




The biophysical forces required to enter (and cross) a low dielectric are no different from those required to bind to a hydrophobic pocket of a protein

- Making and breaking H-bonds
- ‘hydrophobic’ interactions
- Polarisation/ polarisability

Biophysical arguments alone cannot realistically discriminate mechanisms

Halothane affects narcosis in part via a TREK-1 K⁺ channel



Heurteaux et al. *EMBO J* 23, 2684-95 (2004)



Huge differences in uptake in different cell and tissue types

In Support of the Pre-eminence of Transporter-mediated Uptake





- 1) The existence of many proteins involved in drug efflux, which illustrates the widespread existence of the ability of natural proteins to transport xenobiotic drugs.
- 2) **The demonstration of the requirement of carriers for molecules (such as lipophilic cations) that had been assumed on biophysical grounds to cross biological membranes without them.**
- 3) **The fact that drugs do concentrate in specific tissues and do not, in fact, leak out as they would if transmembrane diffusion on the basis of log P alone was the whole (or even most of) the story.**
- 4) The increasing and by now abundant evidence from specific cases that particular drugs do in fact enter cells via identified carrier molecules for which they are not the 'natural' ligand.
- 5) The ability to enhance permeability substantially by modifying the drug chemically to form a prodrug that can act as a substrate for drug carriers and thereby enter cells.

“Lipophilic cations”



“Lipophilic cations” had been assumed on biophysical grounds to cross biological membranes without the need of transporters

Uptake of the lipophilic cation dibenzylidimethyl ammonium (DDA⁺) is mediated via the **xxx** transport system.



It is not *a priori* easy to guess from structures which xenobiotics use which carriers, though these can be rationalised post hoc via QSAR!

Barts, P. W. J. A., Hoeberichts, J. A., Klaassen, A. & Borst-Pauwels, G. W. F. H. (1980). Uptake of the lipophilic cation dibenzylidimethylammonium into *Saccharomyces cerevisiae*. Interaction with the thiamine transport system. *Biochim Biophys Acta* **597**, 125-36.

Multiple influx and efflux transporters



Jindal et al. *BMC Microbiology* (2019) 19:195
<https://doi.org/10.1186/s12866-019-1561-0>

BMC Microbiology

RESEARCH ARTICLE

Open Access

Involvement of multiple influx and efflux transporters in the accumulation of cationic fluorescent dyes by *Escherichia coli*




Srijan Jindal^{1,2,3}, Lei Yang⁴, Philip J. Day^{2,3} and Douglas B. Kell^{1,2,4,5*}




53

Two membrane-permeant cationic dyes



3,3'-Dipropylthiadicarbocyanine iodide
 ('**carbocyanine**' or diS-C3(5))




Sybr Green




54

Flow Cytometry




55

Flow Cytometry and Fluorescence – many dyes



56

Carbocyanine uptake into *E. coli* as assessed by flow cytometry




Jindal et al. (2019) BMC Microbiol 19, 195



57

Carbocyanine uptake in *E. coli* with single-gene knockouts



Jindal et al. (2019) BMC Microbiol 19, 195




58

SYBR Green vs diSC3(5) uptake in different *E. coli* knockouts



70-fold variation



Jindal et al. (2019) BMC Microbiol 19, 195



59

Exp Op Drug Metab Toxicol (2011) 7:137-146




Expert Opinion

Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review

1. Introduction
2. Casopitant: case study
3. Accumulation of drug related material in tissues and its effects

Mario Pellegatti¹ & Sabrina Pagliaruso¹

¹GlaxoSmithKline, Via Fleming 2, Verona, Italy



"Zurisa"





Figure 3. Concentration of drug related material in dog tissues after repeated oral doses of casopitant at 40 mg/kg. *After a recovery period of 20 days.




60

Differences in serum metabolite uptake and secretion across human cell lines




Unpublished mass spectrometric analysis, Marina Wright Muelas (Liverpool)

Imatinib distribution in mouse kidney



Tissue-selective expression of **SLC7A3**




cationic amino acid transporter, γ^+ system

http://www.proteinatlas.org/tissue_profile.php?antibody_id=3629

Two livers with the same **gross PK/PD**

Heterogeneous distributions of a drug in an organ can lead to a toxicity or a lack of efficacy while retaining the same gross PK/PD



Total amount of drug in organ is the same, but in (b) it has **no efficacy** in most of the cells (as it does not enter them all) and **may exhibit toxicity** (as it is more highly concentrated in some)

Two ramifications of the view that drug transport is largely carrier-mediated



- **Successful (marketed) drugs may be more like endogenous (intermediary) metabolites**
- **But how do we tell which transporters are used by particular drugs?**

Carriers involved in the cellular uptake of drugs




Lanthaler et al. *BMC Biology* 2011, 9:70
<http://www.biomedcentral.com/1741-7007/9/70>


Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast


Karin Lanthaler^{1,2,3†}, Elizabeth Bilsland^{4†}, Paul D Dobson^{1,2}, Harry J Moss⁴, Pinar Pir^{3,4}, Douglas B Kell^{1,2} and Stephen G Oliver^{3,4*}

A) Effect of yeast gene deletions on DPI toxicity



B) Effect of *nrt1* deletion on DPI toxicity and its rescue by nicotinic acid





NB – even this approach will miss cases in which there are very many transporters – as is probably often true for marketed drugs



69

The solute carrier SLC35F2 enables YM155-mediated DNA damaged toxicity




ARTICLE
PUBLISHED ONLINE: 27 JULY 2014 | DOI: 10.1038/NCHEM1396

nature
chemical biology

10, 768-773 (2014)

The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity

Georg E Winter¹, Branka Radic^{1,4}, Cristina Mayor-Ruiz^{1,4}, Vincent A Blomen², Claudia Trefzer¹, Richard K Kandasamy¹, Kilian V M Huber¹, Manuela Gridling¹, Doris Chen¹, Thorsten Klampff¹, Robert Kratochvíl¹, Stefan Kubicek¹, Oscar Fernandez-Capetillo², Thijn R Brummelkamp^{1,3} & Giulio Superti-Furga^{1*}



70

The solute carrier SLC35F2 enables YM155-mediated DNA damaged toxicity



ARTICLE


PUBLISHED ONLINE: 27 JULY 2014 | DOI: 10.1038/NCHEMBO.1390

nature
chemical biology

10, 768–773 (2014)

The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity

Georg E Winter¹, Branka Radić^{1,4}, Cristina Mayor-Ruiz^{1,4}, Vincent A Blomen², Claudia Trefzer¹, Richard K Kandasamy¹, Killian V M Huber¹, Manuela Gridling¹, Doris Chen¹, Thorsten Klampff¹, Robert Kralovics³, Stefan Kubicek¹, Oscar Fernandez-Capetillo⁵, Thijs R Brummelkamp^{1,3} & Giulio Superti-Furga^{1*}



Note the negligible background activity



71

Of course the converse is also true

drugs with transporters only in one tissue can be targeted there



Journal of
**Medicinal
Chemistry**


JMC 55, 1318–1333 (2012)

Article

pubs.acs.org/jmc

Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn,^{*,†} Angel Guzman-Perez,[‡] John Litchfield,[‡] Robert Aiello,[‡] Judith L. Treadway,[‡]




- Inhibiting gluokinase non-selectively is toxic
- Isozymes essentially identical in liver and pancreas
- Substrate for OATPs in liver
- Hepatocyte: pancreas ratio ~50:1....



72

Proposed partial mode of action of fragments in enhancing gemcitabine toxicity in Panc1 cells



Influx/efflux transporter expression ratio insufficient for full toxicity

frontiers
in Pharmacology

8, 155 (2017)

ORIGINAL RESEARCH
published: 06 March 2017
doi: 10.3389/fphar.2017.00155



Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine

Justine M. Crixell^{1,2}, Steve O'Hagan^{3,4}, Philip J. Day^{1,2} and Douglas B. Kell^{5,6,7*}

Drug varies transporter expression → increased toxicity



73

74

Audience Survey Question

ANSWER THE QUESTION ON BLUE SCREEN IN ONE MOMENT



What are mainly the 'real' substrates of these drug transporters?


- Pharmaceutical drugs
- Endogenous metabolites
- Exogenous natural products
- Fluorescent compounds
- Other (Tell us more in the chat)

** If your answer differs greatly from the choices above tell us in the chat!*


Drug-metabolite similarities



Chlorpromazine



Thiamine




- Encode as a string of 1s and 0s (various encodings exist)
- Compare strings, commonly as Jaccard/Tanimoto distance of shared bits/ total bits

Drug-metabolite similarities




Chlorpromazine



0.485


Thiamine




0.33

0.50


MACCS 166 ENCODING




O'Hagan & Kell, (2015) Metabolomics 11, 323-329




Cumulative Closest Tanimoto distance for different fingerprints




Rank Order of Layered_TS vs MACCS_TS



Rank Order of RDKit_TS vs MACCS_TS




Sum of ranks vs MACCS max_TS implies 0.75-0.8 cutoff



83

Normalised MACCS rank order vs MACCS_TS full for pharmaceutical drugs vs endogenites or natural products




84

Maximum rank with TYPICAL encoding, 196k NPs



Maximum normalised rank



The 'real' substrates of most SLCs are **natural products**

O'Hagan & Kell, (2017) ADME & DMPK 5, 85-125

Unlocking SLC Transporters



nature reviews
drug discovery

COMMENT · 07 APRIL 2020

<https://re-solute.eu/>

The RESOLUTE consortium: unlocking SLC transporters for drug discovery

The Innovative Medicines Initiative Consortium RESOLUTE has started to develop tools and produce data sets to de-orphanize transporters in the solute carrier protein (SLC) superfamily, thereby lowering the barrier for the scientific community to explore SLCs as an attractive drug target class.

Giulia Superfi-Furga¹, Daniel Lackner, Tabea Wiesner, Alvaro Ingles-Prieto, Barbara Barbosa, Enrico Girardi, Ulrich Goldmann, Bettina Gürtl, Kristaps Klavins, Christoph Klimek, Sabrina Lindinger, Eva Liliéro-Petes, André C. Müller, Svenja Orstein, Gregor Redinger, Daniela Reil, Vitya Sedlyarov, Genot Wolf, Matthew Crawford, Robert Everley, David Hepworth, Sherngping Liu, Stephen Noell, Mary Piotrowski, Robert Stanton, Hui Zhang, Salvatore Corallino, Andrea Faddo, Maria Invidioso, Giovanna Maresca, Loredana Redaelli, Francesca Sassone, Lia Scarabottolo, Michela Stucchi, Paola Taroni, Sara Tremolada, Helena Betoulis, Andreas Becker, Eckhard Bendec, Yung-Ning Chang, Alexander Ehemann, Anke Müller-Fahrnow, Vera Plötter, Diana Zindel, Bradford Hamilton, Martin Lentze, Diana Santacruz, Coralie Viollet, Charles Whitehurst, Kai Johansson, Philipp Leippe, Birgit Baumgarten, Lena Chang, Yvonne Ibig, Martin Pfaffel, Jürgen Reinhardt, Julian Schönblatt, Paul Selzac, Klaus Seuwen, Charles Bettensbourg, Bruno Blton, Jörg Czech, Héliane de Foucauld, Michel Didier, Thomas Lichez, Vincent Mikol, Anjie Pommerehne, Frédéric Pouch, Veerangouda Yalgara, Aled Edwards, Brandon J. Bongers, Laura H. Heitman, Ad P. IJzerman, Huub J. Sijben, Gerard J.P. van Westren, Justine Grieki, Douglas B. Kell, Farah Mughal, Neil Swainston, Marina Wright Muslas, Tina Bohstedt, Nicola Burgess-Brown, Liz Carpenter, Katharina Dürs, Jesper Hansen, Andrea Scacico, Giulia Banci, Claire Colea, Daniela Digles, Gerhard Eckel, Barbara Fizi, Viktoria Gamgänger, Melanie Grandits, Riccardo Martini, Florentina Troger, Patrick Altmatt, Cédric Doucraux, Franz Dörenberger, Vanja Manolova, Anna-Lena Steck, Hanna Sundström, Maria Wilhelm & **Cláire M. Stegeman**²

Conclusions



- The human metabolic network contains many transporters of unknown specificity, and often not for endogenites
- **Much** evidence shows that specific drugs do enter cells by known carriers, and probably do so **only** via this route – “bilayer diffusion” is **negligible** and **a myth**
- Carrier-mediated uptake is thus almost certainly the rule and not the exception, and **makes drug and xenobiotic transport a problem of systems biology**
- This has **considerable** implications for the design of safe and efficacious drugs that behave at a **SYSTEMS** level
- We thus need to develop systems pharmacology, **especially including expression proteomics of transporters.....**

Recent book – freely downloadable as pdf



<https://osf.io/pnxcx/>

Free ACS Webinars Everyday!

Tomorrow



KITCHEN CHEMISTRY

Lessons from Professional and Recreational Cooks!

FREE Rebroadcast | Fri, May 1 at 2pm ET

ACS Webinars
CLICK • WATCH • LEARN • SHARE

<https://www.acs.org/acswebinars>

89

Free ACS Webinars Everyday!

Coming Next Week



Alternative & Non-Traditional CAREERS
in Chemistry and Related Sciences

Tuesday, May 5, 2020 at 6-7pm IST (India)

Speaker: Anubhav Saxena, Pidilite Industries Limited

Moderator: Deeksha Gupta, American Chemical Society

Register for Free!

What You Will Learn

- How one can plan for a chemistry career in Industry
- Examples of jobs for chemists that exist outside the traditional path
- Additional skills that could be useful while pursuing such career (technical/soft skills etc.)

Navigating Graduate School and Mental Health

Wednesday, May 6, 2020 at 2-3pm ET

Speakers: Maral Mousavi, University of Southern California / Philippe Buhlmann, University of Minnesota / Ashley Blystone, Duquesne University / Jennifer Heemstra, Emory University

Moderator: Dorea Reeser, *Chemical & Engineering News*

Register for Free!

What You Will Learn

- Common issues that students face and strategies on how to deal with them
- Advice from the panelists based on their personal and professional experiences
- The chance for the panel to take your questions

SAFER CHEMISTRY EDUCATION at home

Thursday, May 7, 2020 at 2-3pm ET

Speaker: Debbie Decker, UC Davis and Jennifer Bishoff, Frostburg University

Moderator: Ralph Stuart, Keene State College

Register for Free!

What You Will Learn

- Home chemistry learning opportunities
- Safety concerns with home chemistry education
- ACS resources to support science safety education

www.acs.org/acswebinars

90



How Drugs Really Get Into Cells: Why Passive Bilayer Diffusion is a Myth



Douglas Kell
Professor of Systems Biology, Department
of Biochemistry, University of Liverpool



Michael Sinz
Senior Research Fellow,
Bristol-Myers Squibb

Presentation slides are available now! Edited recordings are an exclusive ACS member benefit.

www.acs.org/acswebinars

This ACS Webinar is co-produced with ACS Division of Medicinal Chemistry, American Association of Pharmaceutical Scientists, and ACS Publications.

91



Contact Us:

2107 Wilson Blvd
#700
Arlington, VA 22201

(703)243-2800
aaps@aaps.org

AAPS Membership
membership@aaps.org
(877)998-2277 (AAPS)



WHO WE ARE

Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 7,000 individual members and over 10,000 actively participating stakeholders employed in academia, industry, government, and other pharmaceutical science related research institutes worldwide.

Our mission:

To advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health

Our vision:

Advancing the pharmaceutical sciences to drive prevention and cures.

Our five core values:

Learning, Innovation, Service, Inclusiveness and Integrity.


AAPS is incorporated as a not-for-profit organization under the U. S. Internal Revenue Service Code, 501(c)3 in the District of Columbia.

Members of the American Association of Pharmaceutical Scientists (AAPS) gathered during the 2013 AAPS Annual Meeting and Exposition to discuss why they chose a career in pharmaceutical sciences and how AAPS has helped foster their journey. The I Am AAPS video series displays the diversity of AAPS membership while exhibiting one common goal: to impact global health.

<https://www.aaps.org>

92

Join the Division Today!



For \$25 membership (\$10 for students), You Will Receive:

- A free digital copy of our annual medicinal chemistry review volume (over 680 pages, \$160 retail price)
- Abstracts of MEDI programming at national meetings
- Access to student travel grants and fellowships

Find out more about the ACS MEDI Division! www.acsmedchem.org

93



ACS Webinars™

CLICK • WATCH • LEARN • DISCUSS



@AmericanChemicalSociety



@AmerChemSociety



@AmerChemSociety



<https://www.linkedin.com/company/american-chemical-society>

Contact ACS Webinars® at acswebinars@acs.org

94



ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the American Chemical Society.




Contact ACS Webinars® at acswebinars@acs.org

95

Free ACS Webinars Everyday!

Coming Next Week



Tuesday, May 5, 2020 at 6-7pm IST (India)

Speaker: Anubhav Saxena, Pidilite Industries Limited
Moderator: Deeksha Gupta, American Chemical Society

[Register for Free!](#)

What You Will Learn

- How one can plan for a chemistry career in Industry
- Examples of jobs for chemists that exist outside the traditional path
- Additional skills that could be useful while pursuing such career (technical/soft skills etc.)



Wednesday, May 6, 2020 at 2-3pm ET

Speakers: Maral Mousavi, University of Southern California / Philippe Buhlmann, University of Minnesota / Ashley Blystone, Duquesne University / Jennifer Heemstra, Emory University
Moderator: Dorea Reeser, *Chemical & Engineering News*

[Register for Free!](#)

What You Will Learn

- Common issues that students face and strategies on how to deal with them
- Advice from the panelists based on their personal and professional experiences
- The chance for the panel to take your questions



Thursday, May 7, 2020 at 2-3pm ET

Speaker: Debbie Decker, UC Davis and Jennifer Bishoff, Frostburg University
Moderator: Ralph Stuart, Keene State College

[Register for Free!](#)

What You Will Learn

- Home chemistry learning opportunities
- Safety concerns with home chemistry education
- ACS resources to support science safety education

www.acs.org/acswebinars

96